Recombinant Anti-CD317 x Anti-CD16 Bispecific Antibody (F(ab')2-scFv2) (BABFV-111)

Recombinant Anti-CD317 x Anti-CD16 Bispecific Antibody (F(ab')2-scFv2) is designed to be expressed as two chains combined via a hinge region. The scFv of the anti-CD317 specificity is fused to the C terminus of the anti-CD16 Fab fragment, or vice versa. This format comprises four binding sites (two same scFv regions and two same Fab fragments), two for each antigen. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Multiple myeloma (MM) therapy.

Datasheet INQUIRY

Specifications

Targets

CD317 & CD16

Type

Fab-Fc Fusion Proteins

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Multiple myeloma (MM)

Targets

Target 1

CD317

Gene ID

684

UniProt ID

A0A024R7H5

Alternative Names

CD317; TETHERIN; BST2; bone marrow stromal cell antigen 2; Cluster of differentiation 317

Target 2

CD16

Gene ID

2214

UniProt ID

M9MML0

Alternative Names

FCGR3A; Fc fragment of IgG, low affinity IIIa, receptor (CD16a); CD16; FCG3; CD16A; FCGR3; IGFR3; IMD20; FCR-10; FCRIII; FCGRIII; FCRIIIA; low affinity immunoglobulin gamma Fc region receptor III-A; FcγRIII; FcgammaRIIIA; CD16a antigen; fc-gamma RIII; Fc-gamma RIIIa; Fc-gamma RIII-alpha; igG Fc receptor III-2; Fc gamma receptor III-A; Fc-gamma receptor IIIb (CD16); neutrophil-specific antigen NA; Fc-gamma receptor III-2 (CD 16); immunoglobulin G Fc receptor III; Fc fragment of IgG, low affinity III, receptor for (CD16)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD317 x Anti-CD16 Bispecific Antibody (F(ab')2-scFv2) (BABFV-111). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD317 x Anti-CD16 Bispecific Antibody (F(ab')2-scFv2) (CAT#: BABFV-111)

Specifications

Targets

Customer Reviews and Q&As